Integrated Biobank of Luxembourg

The biobank will now look to get ISO 17025 certification to expand its presence in Europe and internationally. 

NEW YORK (GenomeWeb News) – OncoDNA today said that it will collaborate with the Integrated BioBank of Luxembourg to provide physicians in Luxembourg with access to next-generation sequencing-based testing for cancer.

WaferGen Biosystems said this week that it has been awarded a €1 million ($1.3 million) matching grant by the Luxembourg government to help it expand its European operations, which are headquartered in Luxembourg.

WaferGen BioSystems and the Integrated BioBank of Luxembourg will co-develop molecular signatures for diagnostic research and commercial applications.

The alliance includes a research partnership and a co-development effort. In addition, WaferGen will establish its European Headquarters at the IBBL facilities.

The IBBL is a non-profit biobanking and biotechnology foundation that was started two years ago by three public research centers and the University of Luxembourg, and was developed in collaboration with the Translational Genomics Research Institute. It has been collecting and distributing a wide range of biological samples, focusing initially on cancer.

The Integrated Biobank of Luxembourg will use the SOLiD system to sequence biospecimen samples.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.